Design Therapeutics (DSGN) grants George Simeon 30,000 stock options at $10.55

Rhea-AI Filing Summary

Design Therapeutics director and 10% owner George Simeon received a grant of stock options covering 30,000 shares of common stock. The options have an exercise price of $10.55 per share and expire on June 8, 2036. They vest in equal monthly installments over 12 months after June 9, 2026, or will be fully vested by the company’s next annual stockholder meeting.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider George Simeon

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	30,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 30,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 30,000 options Exercise price: $10.55 per share Expiration date: June 8, 2036 +2 more

5 metrics

Option grant size 30,000 options Stock Option (right to buy) granted to George Simeon

Exercise price $10.55 per share Exercise price of stock options on common stock

Expiration date June 8, 2036 Option expiration for Simeon’s grant

Vesting period 12 months Equal monthly vesting after June 9, 2026

Total options after grant 30,000 options Total derivative securities following transaction

Key Terms

Stock Option (right to buy), exercise price, vesting, expiration date

4 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy) granted on June 9, 2026"

exercise price financial

"conversion_or_exercise_price of the option is 10.5500 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"shares subject to the option vest in equal monthly installments over 12 months"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date for the option is 2036-06-08T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

George Simeon

(Last) (First) (Middle)

929 MAIN STREET

SUITE 200

(Street)

REDWOOD CITY CALIFORNIA 94063

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Design Therapeutics, Inc. [ DSGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$10.55	06/09/2026		A		30,000		(1)	06/08/2036	Common Stock	30,000	$0	30,000	D

Explanation of Responses:

1. The shares subject to the option vest in equal monthly installments over 12 months following June 9, 2026 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders.

	/s/ Sasha Keough, attorney-in-fact for Simeon George	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Design Therapeutics (DSGN) report for George Simeon?

Design Therapeutics reported that director and 10% owner George Simeon received a grant of stock options for 30,000 shares of common stock. This is a compensation-related award, not an open-market purchase or sale of existing shares.

What is the exercise price of the new DSGN stock options granted to George Simeon?

The granted stock options have an exercise price of $10.55 per share. This means Simeon can buy Design Therapeutics common stock at $10.55 when the options are vested and exercised, regardless of the market price at that time.

How many Design Therapeutics (DSGN) shares are covered by George Simeon’s new option grant?

The option grant covers 30,000 shares of Design Therapeutics common stock. These are potential future shares that can be acquired if Simeon exercises the options after they vest, rather than currently issued common shares.

When do George Simeon’s DSGN stock options vest and become exercisable?

The options vest in equal monthly installments over 12 months following June 9, 2026. However, the filing states they will in any case be fully vested on the date of Design Therapeutics’ next annual meeting of stockholders, if that occurs earlier.

What is the expiration date of the Design Therapeutics (DSGN) options granted to George Simeon?

The stock options granted to George Simeon expire on June 8, 2036. After that expiration date, Simeon would no longer be able to exercise these options to purchase Design Therapeutics common stock at the specified exercise price.

Did George Simeon buy or sell any existing DSGN shares in this Form 4 filing?

The Form 4 shows a grant of stock options classified as an acquisition, not a market trade in existing shares. The transaction code is A, indicating a grant or award, and no open-market purchases or sales of common stock are reported.